<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6854">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03017690</url>
  </required_header>
  <id_info>
    <org_study_id>A-US-52030-358</org_study_id>
    <nct_id>NCT03017690</nct_id>
  </id_info>
  <brief_title>Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)</brief_title>
  <official_title>Lanreotide and Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An observational time and motion study in a clinical oncology setting is utilized in order
      to measure and compare product attributes and overall product efficiency between lanreotide
      and octreotide LAR.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The total time for product preparation and administration</measure>
    <time_frame>Day 1</time_frame>
    <description>Total drug delivery time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total patient wait time for administration</measure>
    <time_frame>Day 1</time_frame>
    <description>For the purposes of this study, &quot;total patient wait time&quot; refers to the time the patient checks in at the infusion room until completion of drug administration and discharge of the patient from the infusion room.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clogging episodes</measure>
    <time_frame>Day 1</time_frame>
    <description>The number of clogging episodes for lanreotide and octreotide LAR will be recorded and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare resource utilization</measure>
    <time_frame>Day 1</time_frame>
    <description>The materials used for the preparation of lanreotide and octreotide LAR will be recorded and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacist and/or nurse satisfaction and product preference</measure>
    <time_frame>Day 1 and at the end of the study (approximately 3 months)</time_frame>
    <description>Assessed by pharmacist and/or nurse completing questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Day 1</time_frame>
    <description>Assessed by patient completing questionnaire</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastroenteropancreatic Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>lanreotide group (Somatuline Depot®)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>octreotide LAR group (Sandostatin LAR®)</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited through US (and potential for Canadian) institutions/clinics
        that commonly treat neuroendocrine tumor patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women must be 18 years of age or older

          -  A current diagnosis of advanced, unresectable GEP-NET

          -  Provided written informed consent to participate in the study

          -  Currently receiving lanreotide or octreotide LAR and has received at least one prior
             injection of current somatostatin analogues (SSA).

        Exclusion Criteria:

          -  Receiving treatment with lanreotide or octreotide LAR as part of a clinical trial

          -  Scheduled to receive a dose of lanreotide or octreotide LAR that would necessitate
             more than 1 injection on the same day

          -  Scheduled to receive any other treatment in the infusion center/room on the same day
             and as part of the same appointment

          -  Known hypersensitivity to somatostatin analogues
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Ray, Pharm.D, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ipsen Recruitment Enquiries</last_name>
    <email>clinical.trials@ipsen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tuscan</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 7, 2017</lastchanged_date>
  <firstreceived_date>December 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
